e-Therapeutics unveils results of its strategic review under new chief executive
e-Therapeutics plans to control its costs by reducing the number of self-funded discovery programmes from six to two
Company
e-Therapeutics PLC
LON:ETX
e-Therapeutics PLC is integrating computational power and biology to accelerate the discovery of life-transforming RNAi medicines. The company has developed and validated a powerful computational approach to drug discovery, leveraging our industry-leading expertise in network biology to fully capture and interrogate human disease complexity. e-Therapeutics' multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support.
153 stories · page 6 of 8
Archive
Proactive news round-up: Lombard Risk Management, Acal, Symphony Environmental Technologies …
A glance at some of the stories on the Proactive newswire today
Drug developer e-Therapeutics streamlines its operation
“We are now focusing on our core strengths around our unique drug discovery platform and the discovery of novel preclinical drugs," said chairman Iain Ross.
Archive
Day ahead: Retailers at opposite ends of shopping spectrum in focus
Luxury group Burberry PLC will deliver a pre-close season trading update, while Primark discount clothing chain owner Associated British Foods PLC delivers its first-half results
Archive
Primark to keep the ball rolling nicely at Associated British Foods
Week ahead; Associated British Foods , Sky , Unilever Burberry, Reckitt Benckiser...
Triad Group shares surge after saying it expects full year profit growth
Some of the largest share price rises and falls in London at 4pm: Triad Group, Hardide, Weatherly
First day for new e-Therapeutics boss
Dr Raymond Barlow arrives from Amgen, where he held a senior role
FTSE 100 finishes lower as Fed's easy money set to end
The index of blue-chip shares succumbed to selling pressure
Archive
Proactive news round-up: EG Solutions, Avation, Gulfsands Petroleum ...
A glance at some of the stories on the Proactive newswire today.
Metal Tiger strongly extends yesterday's leap; Laura Ashley drops
The main risers and fallers around 2.45pm included Metal Tiger, CloudTag, Laura Ashley ...
Investments and investor services
FTSE shares ease with lower Wall St and ex-dividend stocks
FTSE 100 shares closed lower, dragged down by weaker US stocks and a flurry of ex-dividend stocks in London
Archive
Proactive news round-up: Orogen Gold, Braveheart Investment, Concepta ...
A glance at some of the stories on the Proactive newswire today
e-Therapeutics appoints Amgen heavy-hitter as new CEO
Dr Raymond Barlow brings with him a “broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector”, ETX said.
Archive
Proactive news round-up: Range Resources, LGO Energy, Corero Network Security ...
A glance at some of the stories on the Proactive newswire today
e-Therapeutics director buys shares with fees
The group said he subscribed for 36,917 new shares at 7.45p each worth around £2,750.
Risers & Fallers: Crossrider, EVR Holdings, Scotgold...
Major share price risers and fallers in London at 3.45pm
e-Therapeutics refocused and well-funded
The company underwent something of a transition in the first six months of the year, reorganising its board and shifting its focus
Change of focus leads to departure of development director at e-Therapeutics
Pharma veteran Steve Self is moving on following the company's decision to focus on its discovery platform
E-Therapeutics' chief executive steps down
Iain Ross, the current chairman, will take on an executive role while the company looks for a new chief executive.
Proactive news highlights: Deltex Medical, e-Therapeutics, Motif Bio, Sula Iron and more...
Deltex Medical Group has hailed the “superb results”, Tissue Regenix beefs up its board and MySQUAR updates on the success of its first game.